Drug DevelopmentThe FDA has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for treatment of polycythemia vera (PV).
Legal DevelopmentsA crucial legal win may signal additional upside not factored into forecasts.
Regulatory RelationsThe FDA may elect to remove the partial clinical hold on tradipitant in motion sickness, thus clearing the path for Vanda to furnish additional long-term safety data to the agency in support of approval.